George Eric Davis Biomarin Pharmaceutical Inc (BMRN) insider trading activity

George Eric Davis is EVP, Chief Legal Officer of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 56,157 shares of BMRN, which is worth approximately $4.62 Million. The most recent transaction as insider was on May 28, 2024, when has been sold 40,850 shares (Common Stock) at a price of $74.87 per share, resulting in proceeds of $3,058,439. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.2K

0.54% 3M change

30.22% 12M change

Total Value Held $4.62 Million

George Eric Davis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 28 2024	SELL Open market or private sale	$3,058,439 $74.87 p/Share	40,850 Reduced 42.11%	56,157 Common Stock
May 28 2024	BUY Exercise of conversion of derivative security	$2,577,635 $63.1 p/Share	40,850 Added 29.63%	97,007 Common Stock
May 02 2024	SELL Open market or private sale	$157,268 $85.01 p/Share	1,850 Reduced 3.19%	56,157 Common Stock
May 02 2024	BUY Exercise of conversion of derivative security	$116,735 $63.1 p/Share	1,850 Added 3.09%	58,007 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$20,663 $68.65 p/Share	301 Added 0.53%	56,157 Common Stock
Mar 28 2024	SELL Open market or private sale	$2,173,340 $88.34 p/Share	24,602 Reduced 30.58%	55,856 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$1,819,895 $83.87 p/Share	21,699 Reduced 21.24%	80,458 Common Stock

Mar 15 2024	BUY Grant, award, or other acquisition	-	10,260 Added 9.13%	102,157 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	36,187 Added 28.25%	91,897 Common Stock
Dec 13 2023	SELL Open market or private sale	$1,311,709 $95.3 p/Share	13,764 Reduced 19.81%	55,710 Common Stock
Aug 08 2023	SELL Open market or private sale	$983,620 $89.42 p/Share	11,000 Reduced 13.67%	69,474 Common Stock
May 16 2023	SELL Bona fide gift	-	210 Reduced 0.26%	80,474 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$21,200 $66.88 p/Share	317 Added 0.39%	80,684 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$1,864,183 $93.41 p/Share	19,957 Reduced 19.89%	80,367 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$265,413 $87.74 p/Share	3,025 Reduced 2.93%	100,324 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	8,900 Added 7.93%	103,349 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	37,724 Added 28.54%	94,449 Common Stock
Feb 24 2023	BUY Exercise of conversion of derivative security	$99,951 $67.81 p/Share	1,474 Added 2.53%	56,725 Common Stock
Aug 09 2022	SELL Open market or private sale	$4,923,394 $96.13 p/Share	51,216 Reduced 48.11%	55,251 Common Stock
Aug 09 2022	BUY Exercise of conversion of derivative security	$3,222,738 $67.81 p/Share	47,526 Added 31.62%	102,777 Common Stock
Jul 08 2022	SELL Open market or private sale	$665,820 $90.0 p/Share	7,398 Reduced 11.15%	58,941 Common Stock
May 02 2022	SELL Open market or private sale	$1,233,592 $80.38 p/Share	15,347 Reduced 18.79%	66,339 Common Stock
May 02 2022	BUY Exercise of conversion of derivative security	$574,899 $37.46 p/Share	15,347 Added 15.82%	81,686 Common Stock
Apr 29 2022	BUY Grant, award, or other acquisition	$21,282 $62.41 p/Share	341 Added 0.51%	66,339 Common Stock
Apr 25 2022	BUY Exercise of conversion of derivative security	$99,981 $37.46 p/Share	2,669 Added 3.89%	65,998 Common Stock

GED

George Eric Davis

EVP, Chief Legal Officer

San Rafael, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMRN shares.

Notify only if

Value

Insider Trading

Get notified when an Biomarin Pharmaceutical Inc insider buys or sells BMRN shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOMARIN PHARMACEUTICAL INC

Track Activities on BMRN

Account